The OAS–RNase L pathway: Insights from experiments of nature
Science Immunology · 09.01.2026 · 11 (115)
DOI: 10.1126/sciimmunol.ads9407 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Immunology, erschienen am 09.01.2026. Verfasst von Danyel Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065, USA. Hauptthemen laut MEDLINE: 2',5'-Oligoadenylate Synthetase, Endoribonucleases, SARS-CoV-2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIAID NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
The 2′-5′ oligoadenylate synthetases (OASs) are type I interferon–inducible enzymes that, with ribonuclease L (RNase L), have been studied in the context of their coupled action as antiviral effectors. RNase L degrades host and viral ssRNA, affecting diverse cellular processes including translational arrest, interferon response, and apoptosis, all of which are thought to restrict viral replication. Recent studies of recessive inborn errors of human OAS1, OAS2, and RNase L, however, revealed that for SARS-CoV-2 infection, the main protective action of this pathway in natura may be through restricting phagocyte-driven postviral inflammation rather than restricting early viral replication in the respiratory tract. This finding is consistent with the identification of gain-of-function OAS1 mutations in humans with autoinflammation also driven by myeloid cells. Here, we retrace the investigation of the OAS–RNase L pathway, focusing on these recent in natura studies in humans that reposition the pathway as a determinant of the inflammatory response under natural conditions of infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065, USA.
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France.
- Paris City University, Imagine Institute, Paris, France.
- Department of Molecular, Cellular, and Developmental Biology, University of Toledo, 2801 West Bancroft Street, Toledo, OH 43606, USA.
- Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
- Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD 20892, USA.
ORCID-Profile: Danyel Lee, Krishnamurthy Malathi, Koji Nakajima, Aurélie Cobat, Tomohiro Morio, Jean-Laurent Casanova, Shen-Ying Zhang
Förderung
- NCATS NIH HHS
- NIAID NIH HHS
- Howard Hughes Medical Institute
- National Institutes of Health
- National Center for Advancing Translational Sciences
- Georgia Clinical and Translational Science Alliance
- Association Neurofibromatoses et Recklinghause
- Fondation pour la Recherche Médicale
Zitieren
APA
Lee, D., Malathi, K., Okano, T., Nakajima, K., Cobat, A., Morio, T., Casanova, J. L., & Zhang, S. Y. (2026). The OAS–RNase L pathway: Insights from experiments of nature. Science Immunology, 11(115). https://doi.org/10.1126/sciimmunol.ads9407
Vancouver
Lee D, Malathi K, Okano T, Nakajima K, Cobat A, Morio T, et al. The OAS–RNase L pathway: Insights from experiments of nature. Science Immunology. 2026;11(115). doi:10.1126/sciimmunol.ads9407
BibTeX
@article{Lee2026,
author = {Lee, Danyel and Malathi, Krishnamurthy and Okano, Tsubasa and Nakajima, Koji and Cobat, Aurélie and Morio, Tomohiro and Casanova, Jean-Laurent and Zhang, Shen-Ying},
title = {The OAS–RNase L pathway: Insights from experiments of nature},
journal = {Science Immunology},
year = {2026},
volume = {11},
number = {115},
doi = {10.1126/sciimmunol.ads9407}
}
EUVIMED